Equities
  • Price (EUR)0.376
  • Today's Change-0.036 / -8.74%
  • Shares traded3.00k
  • 1 Year change+10.56%
  • Beta--
Data delayed at least 15 minutes, as of Mar 28 2024 19:22 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-70.45m
  • Incorporated2016
  • Employees50.00
  • Location
    Cybin Inc100 King Street West, Suite 5600TORONTO M5X 1C9CanadaCAN
  • Phone+1 (604) 806-0626
  • Fax+1 (604) 806-0626
  • Websitehttps://www.cybin.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
since
announced
Transaction
value
Small Pharma IncDeal completed28 Aug 202328 Aug 2023Deal completed31.71%2.84m
Data delayed at least 30 minutes, as of Mar 28 2024.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.